Browse: Departments   Dates   Agencies  

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Docket ID: [Docket No. 2006N-0037]

NOTICE: NOTICES

DOCUMENT ACTION: Notice.

SUBJECT CATEGORY: Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Proposed Experimental Study of Trans Fat Claims on Foods

DATES: Fax written comments on the collection of information by January 16, 2007.

DOCUMENT SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

SUMMARY: Agency information collection activities; proposals, submissions, and approvals,

SUPPLEMENTAL INFORMATION

In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.
Proposed Experimental Study of Trans Fat Claims on Foods(OMB Control Number 09100533Reinstatement)

FDA is requesting OMB approval of a proposed experimental study of trans fat claims on food products intended to help FDA's Center for Food Safety and Applied Nutrition formulate decisions and policies affecting labeling requirements for trans fat claims on foods.

In the Federal Register of July 11, 2003 (68 FR 41507), FDA issued an advance notice of proposed rulemaking entitled ``Food Labeling: Trans Fatty Acids in Nutrition Labeling; Consumer Research to Consider Nutrient Content and Health Claims and Possible Footnote or Disclosure Statements,'' which requested comments about possible disclosure requirements to accompany nutrient content claims about trans fatty acids that could help consumers make hearthealthy food choices. The proposed experimental study will evaluate the ability of several such disclosure requirements to help consumers make hearthealthy food choices. The results of the proposed experimental study will provide empirical support for possible policy decisions about the need for such disclosures and the appropriate form they should take.

FDA or its contractor will collect and use information gathered from Internet panel samples to evaluate how consumers understand and respond to possible disclosure requirements for trans fat content claims. The distinctive features of Internet panel and shopping mall methodologies for the purpose of the proposed experimental study are that they allow for controlled visual presentation of study materials, experimental manipulation of study materials, and the random assignment of subjects to condition. Experimental manipulation of labels and random assignment to condition makes it possible to estimate the effects of the various possible disclosure requirements while controlling for individual differences. Random assignment ensures that mean differences between conditions can be tested using wellknown techniques such as analysis of variance or regression analysis to yield statistically valid estimates of treatment effect size. The proposed study will be conducted with a convenience sample drawn from a large, national consumer panel with about one million households.

Participants will be adults, age 18 and older, who are recruited for a study about foods and food labels. Each participant will be randomly assigned to 1 of the 144 experimental conditions consisting of fully crossing 8 disclosure conditions, 3 product types, 3 fatty acid profiles and 2 prior knowledge conditions.

[[Page 75555]]

FDA will use the information from the proposed experimental study to evaluate regulatory policy options. The agency often lacks empirical data about how consumers understand and respond to statements they might see in product labeling. The information gathered from this proposed experimental study will be used by the agency to assess likely consumer responses to various disclosure requirements for nutrient content claims.

In the Federal Register of February 6, 2006 (71 FR 6076), FDA published a 60day notice requesting public comment on the information collection that will take place as part of the experimental study. FDA received one letter in response to the notice, containing multiple comments.
(Comment 1) One comment stated that the organization concurs with the objectives of the study and believes the information from this study will be useful to FDA in developing labeling policy to assist consumers with interpretation of trans fat claims in food labeling. Another comment suggested that FDA change the labels used to describe the three fatty acid profiles in the study (``good profile,'' ``medium profile,'' and ``poor profile'') because these descriptors were seen as overly negative. The comment recommended alternative language (``low profile,'' ``medium profile'' and ``high profile'') as a way to ensure that the products are not characterized as ``good foods'' or ``bad foods.''
(Response) This suggestion has been implemented. The terminology suggested in the comment adequately conveys the intended profile differences.
(Comment 2) One comment critiqued the draft Full Information treatment language. The comment criticized the onepage summary because it : (1) Did not identify calories in the discussion of fat as a major source of energy and (2) did not relate the calorie contribution of fat to that of carbohydrates and protein. The comment also criticized the information about sources of trans fat because it omitted mention of natural sources of trans fat in the diet, which the comment suggested would help ensure factually correct and balanced information about sources of trans in the diet. The comment questioned the value of stating that trans fat extends shelflife and has desirable taste characteristics since many saturated fat sources are relatively shelf stable and have desirable taste characteristics.
(Response) FDA agrees and has revised the Full Information treatment to incorporate these concerns. Calories and other sources of energy are now mentioned in the introductory passage. Natural sources of trans fat are now mentioned and the similarity between trans fat and saturated fat in terms of shelflife and taste are now addressed. The revised draft will be included in the study pretest and further revisions will be made if FDA determines they are needed based upon pretest results.
Table 1.Estimated Annual Reporting Burden\1\ No. of Annual Frequency Total Annual Hours per Activity Respondents per Response Responses Response Total Hours Pretest 40 1 40 .25 10 Study 2,880 1 2,880 .25 720 Total ................. ................. ................. ................. 730 \1\ There are no capital costs or operating and maintenance costs associated with this collection of information.

Dated: December 8, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E621317 Filed 121406; 8:45 am]
BILLING CODE 416001S

FOR FURTHER INFORMATION CONTACT Jonna Capezzuto, Office of the Chief Information Officer (HFA250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 3018274659.